CROMOLYN SODIUM

Post-LOE

cromolyn sodium

Design Pharmaceuticals

ANDAINHALATIONSOLUTION

Approved

Apr 2022

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CROMOLYN SODIUM (cromolyn sodium) by Design Pharmaceuticals is clinical pharmacology in vitro and in vivo animal studies have shown that cromolyn sodium inhibits sensitized mast cell degranulation which occurs after exposure to specific antigens. Approved for the management of patients with bronchial asthma, asthma. First approved in 2022.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY In vitro and in vivo animal studies have shown that cromolyn sodium inhibits sensitized mast cell degranulation which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of mediators from mast cells. Studies show that cromolyn sodium…

Indications (2)

the management of patients with bronchial asthma

Worked on CROMOLYN SODIUM at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.